| Literature DB >> 29035316 |
Erick Sierra-Diaz1, Alfredo de Jesus Celis-de la Rosa2, Felipe Lozano-Kasten3, Alejandro Bravo-Cuellar4, Mariana Garcia-Gutierrez5, Hernandez-Flores Georgina6.
Abstract
The presence of albumin in urine has been used for more than four decades as a marker of renal and cardiovascular damage. Most of the information on this marker is related to adults. The prevalence of albuminuria in the pediatric population has been reported as being 2.2-12.8% in some countries. Most research in this field is related to albuminuria and diseases, such as diabetes and hypertension. Using the methodology described by Arksey and O'Malley in 2005, a scoping review was carried out to show that the presence of albumin in urine in the pediatric population might be associated with environmental, demographic, congenital, infectious, and non-infectious factors. The information collected is supported by 74 references present in PubMed. The results reveal the multiple causes associated with albuminuria in the pediatric population. This information can be very useful for clinical practice by adding knowledge about albuminuria behavior in children.Entities:
Keywords: albuminuria; pediatric population; risk factor
Mesh:
Year: 2017 PMID: 29035316 PMCID: PMC5664732 DOI: 10.3390/ijerph14101231
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Keyword combination and PubMed results.
| Key-Words Combination | Number of Hints | Final Selection | |
|---|---|---|---|
| PubMed | Albuminuria, risk factor and children | 298 | 59 |
| PubMed | Albuminuria, risk factor and non-diabetic children | 87 | 12 |
| PubMed | Albuminuria and non-diabetic preschoolers | 291 | 31 |
Characteristics of the studies that only included subjects under 21 years old.
| Author (Year) Country [ref] | Study Design | Sample (Age) | Sample and Method (Albuminuria) |
|---|---|---|---|
| Trasande (2013) USA [ | Cross-sectional analyses | N = 710 (6–19 years) | First morning urine sample. Solid-phase fluorescent immunoassay |
| Tsai (2016) China [ | Cross-sectional analyses | N = 184 (<10 years) | Spot urine sample. |
| Trasande (2014) USA [ | Cross-sectional | N = 667 (6–19 years) | First morning urine sample. Solid-phase fluorescent immunoassay |
| Chan (2012) China [ | Cross-sectional | N = 3102 (1–21 years) | Spot urine sample. Immunoturbidimetric assay |
| Noonan (2002) USA [ | Case-control | N = 159 (6–17 years) | Spot urine sample. Enzyme immunosorbent assay |
| Cardenas (2016) Mexico [ | Cross-sectional sampling | N = 107 (5–12 years) | Spot urine sample. Turbidimetry method on Radox Daytona |
| Kong (2012) China [ | Cohort | N = 120 (12–19 years) | Morning urine sample. Immunoturbidimetric assay |
| Omologa (2013) USA [ | Cohort | N = 366 (1–16 years) | Spot urine sample. Method not described |
| Nascimento (2017) Brazil [ | Cohort | N = 66 (6–12 years) | Two urine samples 6 months apart. Immunoturbidimetric assay |
| Becton (2010) USA [ | Cross-sectional | N = 90 (2–18 years) | Two urine samples 6 months apart. Immunoturbidimetric assay |
| McPherson (2011) USA [ | Cross-sectional | N = 410 (2–21 years) | Spot urine sample. Radioimmunoassay (RIA) |
| Ranque (2014); five countries in sub-Saharan Africa [ | Cross-sectional | N = 2582 | Spot urine sample. HemoCue Albumin 20 system or Siemens Clinitek StatusAnalyzer |
| Di Bonito (2014) Italy [ | Cross-sectional | N = 901 (6–16 years) | First morning urine sample. Kinetic nephelometric method. |
| Lurbe (2013) Spain [ | Cross-sectional | N = 134 (9–18 years) | First morning urine sample. Immunonephelometric assay |
| Radhakishun (2013) | Cross-sectional | N = 408 (3–19 years) | Morning urine sample. Immunochemistry system |
| Nguyen (2013) USA [ | Cross-sectional | N = 2515 (12–19 years) | Morning urine sample. Solid-phase fluorescent immunoassay |
| Varlami (2013) Greece [ | Case-control | N = 129 (2–14 years) | Two urine samples: 10 p.m. and 8 a.m. h. Immunonephelometric assay |
| Wami (2015) Zimbabwe [ | Cross-sectional | N = 298 (1–10 years) | Morning urine sample. Clinitek Microalbumin Reagent Strips |
| Stothard (2008) Zanzibar [ | Cross-sectional | N = 66 (9–15 years) | Mid-morning urine sample. Hemastix_reagent strips and Microalbustix_ reagent strips |
| Sousa-Figueiredo (2009) Unguja, Tanzania [ | Cross-sectional | N = 140 (9–15 years) | Mid-morning urine sample. Albumin-HemoCue photometer |
| Elnojomi (2010) Sudan [ | Cross-sectional | N = 88 (children age not available) | 24-h urine sample. Turbidimetric kit and ELISA |
| Karlen (1996) Sweden [ | Cross-sectional | N = 57 (1.7–17.9 years) | Four urine collection periods lasting 30 min each were obtained in every subject. Solid-phase radioimmunological assay |
| Lopez-Gonzalez (1999) Spain [ | Cohort | N = 90 (1.9–16 years) | Two 24-h urine samples 2 months apart. Laser nephelometry |
| Hanh Thien (2013) Vietnam [ | Prospective descriptive study | N = 429 (5–15 years) | Spot urine sample. ELISA using rabbit anti-human albumin polyclonal antibodies and a human serum albumin standard |
| Sharma (2010) Canada [ | Cohort | N = 48 (3–18 years) | Spot urine samples. Immunoassay |
| Garg (2005) Canada [ | Cohort | N = 19 cases (1–5 years) | Spot urine sample. Solid-phase competitive chemiluminescent enzyme immunoassay |
| Garg (2008) Canada [ | Cohort | N = 19 cases (4–8 years) | Two-first morning urine samples. |
| Ergüven (2008) Turkey [ | Cross-sectional | N = 50 cases (3–19 years) | 24-h urine sample. Immunoturbidimetric assay |
| De Lucas (2006) Spain [ | Prospective | N = 95 (1–17 years) | Spot urine samples. Method not described |
| Shirzai (2014) Turkey [ | Cross-sectional | N = 44 cases (6–16 years) | 24-h urine sample. Nephelometry |
| Kolvek (2014) Slovakia [ | Prospective follow-up study | N = 42 (mean 11.3 years) | 24-h urine sample. Method not described |
| Sharp (1998) USA [ | Cross-sectional | N = 103 cases (mean 11.2 years) | Spot urine sample. Radioimmunoassay (RIA) |
| Cadnapaphornchai (2009) USA [ | Clinical Trial | N = 85 (4–21 years) | Two 24-h urine sample. Method not described |
| Selistre (2012) France [ | Cross-sectional | N = 52 (1–17 years) | Second-morning urine sample. Nephelometry, BM2 |
| Lama (2003) Italy [ | Retrospective | N = 100 (mean 11.5 years) | Two 24-h urine samples. Enzyme immunoassay |
| Gonzalez (2007) England [ | Retrospective | N = 176 (0–11.9 years) | Spot urine sample (MNS). Method not described |
| Davies (1984) England [ | Cross-sectional | N = 400 (4–16 years) | 24-h urine sample. ELISA |
| Gracchi (2015) The Netherlands [ | Cohort | N = 1352 (24–60 months) | Pantyliners. Nephelometry |
| Wu (2014) China [ | Cross-sectional | N = 1986 (6–19 years) | Morning spot urine sample. Immunoturbidimetric assay |
| Trachtenberg (2007) USA [ | Secondary analysis of a clinical trial | N = 534 (6–10 years) | Two urine samples 2 years apart. Nephelometric immunochemical methods |
| Kim (2017) Australia [ | Cohort | N = 3418 | Spot urine sample. |
| Haysom (2007) Australia [ | Cross-sectional | N = 2266 (4–14.8 years) | Morning urine sample. Dipsticks Clinitek 50 machine |